These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 28419191)
1. PPARδ promotes tumor progression via activation of Glut1 and SLC1-A5 transcription. Zhang W; Xu Y; Xu Q; Shi H; Shi J; Hou Y Carcinogenesis; 2017 Jul; 38(7):748-755. PubMed ID: 28419191 [TBL] [Abstract][Full Text] [Related]
2. Metformin inhibits PPARδ agonist-mediated tumor growth by reducing Glut1 and SLC1A5 expressions of cancer cells. Ding J; Gou Q; Jin J; Shi J; Liu Q; Hou Y Eur J Pharmacol; 2019 Aug; 857():172425. PubMed ID: 31150647 [TBL] [Abstract][Full Text] [Related]
3. PPARα Promotes Cancer Cell Glut1 Transcription Repression. You M; Jin J; Liu Q; Xu Q; Shi J; Hou Y J Cell Biochem; 2017 Jun; 118(6):1556-1562. PubMed ID: 27918085 [TBL] [Abstract][Full Text] [Related]
4. Metabolic regulation of osteoclast differentiation and function. Indo Y; Takeshita S; Ishii KA; Hoshii T; Aburatani H; Hirao A; Ikeda K J Bone Miner Res; 2013 Nov; 28(11):2392-9. PubMed ID: 23661628 [TBL] [Abstract][Full Text] [Related]
5. AMPK phosphorylates PPARδ to mediate its stabilization, inhibit glucose and glutamine uptake and colon tumor growth. Ding J; Gou Q; Jia X; Liu Q; Jin J; Shi J; Hou Y J Biol Chem; 2021 Sep; 297(3):100954. PubMed ID: 34270958 [TBL] [Abstract][Full Text] [Related]
6. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis. Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532 [TBL] [Abstract][Full Text] [Related]
7. Physical and functional interactions between the serotonin transporter and the neutral amino acid transporter ASCT2. Seyer P; Vandermoere F; Cassier E; Bockaert J; Marin P Biochem J; 2016 Jul; 473(13):1953-65. PubMed ID: 27143784 [TBL] [Abstract][Full Text] [Related]
8. PPARα agonist alleviates tumor growth and chemo-resistance associated with the inhibition of glucose metabolic pathway. Gou Q; Dong C; Jin J; Liu Q; Lu W; Shi J; Hou Y Eur J Pharmacol; 2019 Nov; 863():172664. PubMed ID: 31539552 [TBL] [Abstract][Full Text] [Related]
9. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Fuchs BC; Bode BP Semin Cancer Biol; 2005 Aug; 15(4):254-66. PubMed ID: 15916903 [TBL] [Abstract][Full Text] [Related]
10. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838 [TBL] [Abstract][Full Text] [Related]
11. GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. Sun HW; Yu XJ; Wu WC; Chen J; Shi M; Zheng L; Xu J PLoS One; 2016; 11(12):e0168907. PubMed ID: 28036362 [TBL] [Abstract][Full Text] [Related]
12. Targeting glutamine transport to suppress melanoma cell growth. Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984 [TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure. Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586 [TBL] [Abstract][Full Text] [Related]
14. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Al-Khalili L; Bouzakri K; Glund S; Lönnqvist F; Koistinen HA; Krook A Mol Endocrinol; 2006 Dec; 20(12):3364-75. PubMed ID: 16945991 [TBL] [Abstract][Full Text] [Related]
15. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. Yoo HC; Park SJ; Nam M; Kang J; Kim K; Yeo JH; Kim JK; Heo Y; Lee HS; Lee MY; Lee CW; Kang JS; Kim YH; Lee J; Choi J; Hwang GS; Bang S; Han JM Cell Metab; 2020 Feb; 31(2):267-283.e12. PubMed ID: 31866442 [TBL] [Abstract][Full Text] [Related]
16. 1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell. Zhou X; Zheng W; Nagana Gowda GA; Raftery D; Donkin SS; Bequette B; Teegarden D J Steroid Biochem Mol Biol; 2016 Oct; 163():147-56. PubMed ID: 27154413 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. Hong SY; Yu FX; Luo Y; Hagen T Cell Signal; 2016 May; 28(5):377-383. PubMed ID: 26826652 [TBL] [Abstract][Full Text] [Related]
18. Conjugated linoleic acid (CLA) promotes endurance capacity via peroxisome proliferator-activated receptor δ-mediated mechanism in mice. Kim Y; Kim D; Park Y J Nutr Biochem; 2016 Dec; 38():125-133. PubMed ID: 27736732 [TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor δ improves porcine blastocyst hatching via the regulation of fatty acid oxidation. Guo J; Lu WF; Liang S; Choi JW; Kim NH; Cui XS Theriogenology; 2017 Mar; 90():266-275. PubMed ID: 28166979 [TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Yin Y; Russell RG; Dettin LE; Bai R; Wei ZL; Kozikowski AP; Kopelovich L; Glazer RI Cancer Res; 2005 May; 65(9):3950-7. PubMed ID: 15867396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]